Article
Di Maria Jiang, Kelvin K. W. Chan, Raymond W. Jang, Christopher Booth, Geoffrey Liu, Eitan Amir, Robert Mason, Louis Everest, Elena Elimova
Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022
Summary
- Importance: Evaluating the cost-effectiveness of adjuvant therapies based on the cost per event averted.
- Objective: To assess the costs per event averted for anticancer drugs approved by the FDA between January 2018 and March 2022.
- Design, Setting, and Participants:
- Cross-sectional study of FDA approvals.
- Included randomized trials of anticancer drugs for adjuvant treatment of solid tumors.
- Exclusions: Treatments of nonsolid tumors, nonrandomized/noncontrolled trials, and unpublished trials.
- Outcomes and Measures:
- Cost per event averted.
- Monthly cost and cost per patient for each drug.
- Primary clinical end points and trial design.
- Results:
- 11 approvals were analyzed.
- No overall survival benefit demonstrated; approvals based on surrogate end points.
- Median cost per event averted: $1,610,000 (range: $820,000 to $2,640,000).
- Median cost of complete adjuvant treatment: $158,000 per patient.
- Conclusions and Relevance:
- High costs per event averted for adjuvant anticancer agents.
- Limited widespread or global use without improvements in efficacy or reductions in price.
Globally, the price of cancer drugs is on an upward trajectory, with forecasts of global oncology therapeutic sales reaching $250 billion by 2024. In the US, the Centers for Medicare and Medicaid Services estimates that spending on healthcare will increase from USD 3.6 trillion in 2018 to approximately 6 trillion in 2027, approaching 20% of the gross domestic product, with the costs of cancer drugs playing a substantial role.
The financial burden of these increasing costs falls upon patients and societies. Recent analyses have examined the association between the increasing costs of these anticancer agents and the benefits they deliver to patients. These analyses call into question whether increased costs translate directly into improved survival or improved quality of life for patients.
anticancer drugs, adjuvant therapy, FDA approvals, cost per event averted, surrogate endpoints, oncology drug costs
Related Topics
You May Also Like
Di Maria Jiang, Kelvin K. W. Chan, Raymond W. Jang, Christopher Booth, Geoffrey Liu, Eitan Amir, Robert Mason, Louis Everest, Elena Elimova
Article
Yafang Huanga, Weiyi Xiongb, Jingwei Zhaoa, Wentao Lia, Li Mac, Hao Wua
Early phase clinical trial played a critical role in the Food and Drug Administration-approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary